Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.

Wendelien B. Oswald, Thomas Geisbert, Kelly J. Davis, Joan B. Geisbert, Nancy J. Sullivan, Peter B. Jahrling, Paul W.H.I. Parren, Dennis R. Burton

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of 50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment. Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody.

Original languageEnglish (US)
JournalPLoS Pathogens
Volume3
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Neutralizing Antibodies
Haplorhini
Infection
Antibodies
Monoclonal Antibodies
Macaca
Macaca mulatta
Viruses
Guinea Pigs

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Oswald, W. B., Geisbert, T., Davis, K. J., Geisbert, J. B., Sullivan, N. J., Jahrling, P. B., ... Burton, D. R. (2007). Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathogens, 3(1). https://doi.org/10.1371/journal.ppat.0030009

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. / Oswald, Wendelien B.; Geisbert, Thomas; Davis, Kelly J.; Geisbert, Joan B.; Sullivan, Nancy J.; Jahrling, Peter B.; Parren, Paul W.H.I.; Burton, Dennis R.

In: PLoS Pathogens, Vol. 3, No. 1, 01.2007.

Research output: Contribution to journalArticle

Oswald, WB, Geisbert, T, Davis, KJ, Geisbert, JB, Sullivan, NJ, Jahrling, PB, Parren, PWHI & Burton, DR 2007, 'Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.', PLoS Pathogens, vol. 3, no. 1. https://doi.org/10.1371/journal.ppat.0030009
Oswald, Wendelien B. ; Geisbert, Thomas ; Davis, Kelly J. ; Geisbert, Joan B. ; Sullivan, Nancy J. ; Jahrling, Peter B. ; Parren, Paul W.H.I. ; Burton, Dennis R. / Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. In: PLoS Pathogens. 2007 ; Vol. 3, No. 1.
@article{80dbbbd7c7524e83a802379b2f125d04,
title = "Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.",
abstract = "Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of 50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment. Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody.",
author = "Oswald, {Wendelien B.} and Thomas Geisbert and Davis, {Kelly J.} and Geisbert, {Joan B.} and Sullivan, {Nancy J.} and Jahrling, {Peter B.} and Parren, {Paul W.H.I.} and Burton, {Dennis R.}",
year = "2007",
month = "1",
doi = "10.1371/journal.ppat.0030009",
language = "English (US)",
volume = "3",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.

AU - Oswald, Wendelien B.

AU - Geisbert, Thomas

AU - Davis, Kelly J.

AU - Geisbert, Joan B.

AU - Sullivan, Nancy J.

AU - Jahrling, Peter B.

AU - Parren, Paul W.H.I.

AU - Burton, Dennis R.

PY - 2007/1

Y1 - 2007/1

N2 - Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of 50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment. Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody.

AB - Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of 50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment. Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of neutralizing antibody.

UR - http://www.scopus.com/inward/record.url?scp=34250333091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250333091&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.0030009

DO - 10.1371/journal.ppat.0030009

M3 - Article

VL - 3

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 1

ER -